Xenetic Biosciences, Inc.

Name: Xenetic Biosciences, Inc. standardized financial statements, quarterly
Creator: Listed

XBIONasdaqCIK 1534525HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$660.6k, Q2 FY2026

Operating income−$971.7k, Q2 FY2026

Net income−$929.7k, Q2 FY2026

Xenetic Biosciences, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	611	672	511	726	614	649	593	590	1,027	766	807	661
Cost of revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	1,021	976	944	934	368	1,042	879	657	756	773	661	552
Operating income	$k	(1,147)	(1,256)	(1,268)	(1,337)	(499)	(1,099)	(942)	(724)	(545)	(623)	(502)	(972)
Interest expense	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$k	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	$k	(1,056)	(1,172)	(1,195)	(1,274)	(437)	(1,055)	(903)	(689)	(510)	(579)	(456)	(930)
Diluted EPS	$ per share	(0.69)	not reported	(0.78)	(0.83)	(0.28)	not reported	(0.59)	(0.45)	(0.33)	not reported	(0.20)	(0.41)
Basic EPS	$ per share	(0.69)	not reported	(0.78)	(0.83)	(0.28)	not reported	(0.59)	(0.45)	(0.33)	not reported	(0.20)	(0.41)

Balance sheet

Cash and equivalents$7.3m, Q1 FY2026

Shareholders' equity$6.1m, Q2 FY2026

Xenetic Biosciences, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	9.8	9.0	7.8	7.3	6.8	6.2	5.2	not reported	not reported	7.9	7.3	not reported
Current assets	$m	11.3	9.6	8.4	8.0	7.0	6.6	5.5	5.4	5.1	8.0	7.6	6.7
Total assets	$m	12.0	10.6	9.4	9.0	8.0	6.9	5.8	5.4	5.1	8.4	7.9	7.0
Current liabilities	$m	1.1	0.8	0.7	1.6	1.0	0.9	0.7	0.9	1.1	1.0	1.0	0.9
Total liabilities	$m	1.1	0.8	0.7	1.6	1.0	0.9	0.7	0.9	1.1	1.0	1.0	0.9
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	10.9	9.8	8.7	7.4	7.0	6.0	5.1	4.5	4.0	7.4	7.0	6.1

Cash flow

Operating cash flow−$875.5k, Q2 FY2026

Xenetic Biosciences, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(950)	(793)	(1,159)	(525)	(459)	(674)	(1,002)	(384)	(658)	(243)	(536)	(875)
Capital expenditure	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)2.29m, Q2 FY2026

Xenetic Biosciences, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	1,432	1,517	1,525	1,533	1,541	1,541	1,542	1,542	1,542	1,542	2,291	2,294

Shares outstanding: 2.34m at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.